A new approach to reduce side effects in treating pediatric brain tumors.
A multifunctional nanomaterial platform for reducing morbidity in medulloblastoma therapy
['FUNDING_R21'] · OREGON HEALTH & SCIENCE UNIVERSITY · NIH-11002003
This study is working on a new way to treat medulloblastoma, a tough brain tumor in kids, by using a special material that can find and attack cancer cells without hurting healthy ones, making treatment safer and more effective.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | OREGON HEALTH & SCIENCE UNIVERSITY (nih funded) |
| Locations | 1 site (PORTLAND, UNITED STATES) |
| Trial ID | NIH-11002003 on ClinicalTrials.gov |
What this research studies
This research focuses on improving treatment for medulloblastoma, a common and aggressive brain tumor in children. It aims to develop a multifunctional nanomaterial that can target cancer cells while minimizing damage to healthy tissue. The approach involves using a self-assembled nanomaterial that generates reactive oxygen species when activated by ultrasound, potentially enhancing the effectiveness of treatment while reducing harmful side effects. By combining imaging capabilities with targeted therapy, this research seeks to improve the quality of life for young patients undergoing treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are children diagnosed with medulloblastoma who are undergoing or are candidates for surgical treatment.
Not a fit: Patients with other types of brain tumors or those who are not eligible for surgical intervention may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer treatment options for children with medulloblastoma, reducing long-term side effects and improving their quality of life.
How similar studies have performed: While the use of nanomaterials in cancer therapy is a growing field, this specific approach utilizing sonodynamic therapy is relatively novel and has not been extensively tested in medulloblastoma.
Where this research is happening
PORTLAND, UNITED STATES
- OREGON HEALTH & SCIENCE UNIVERSITY — PORTLAND, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: YILDIRIM, ADEM — OREGON HEALTH & SCIENCE UNIVERSITY
- Study coordinator: YILDIRIM, ADEM
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.